Global pharma major Eli Lilly and Company is setting up a new ... The first LCCI in the country is in Bengaluru and launched in 2016. “Our teams in India play a pivotal role in driving Lilly ...

Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's disease, a type of chronic inflammatory bowel disease (IBD). The drug, ...

(Reuters) -Eli Lilly's popular obesity drug Zepbound can ... (Reporting by Puyaan Singh in Bengaluru; Editing by Devika Syamnath) ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Through the drug, Pfizer aims to offer patients a more convenient alternative to injectable drugs — Eli Lilly's Zepbound ... (Reporting by Bhanvi Satija in Bengaluru and Michael Erman in New ...

but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound, according to analysts. The Danish drugmaker's U.S.-listed shares dropped 2.8% to $80.72 on Friday ...

SAN FRANCISCO (Reuters) - The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over what President-elect Donald Trump's priorities ...

Recruitment for the new site is underway, and the centre is expected to be operational by mid-2025, it added. LCCI Hyderabad will be Lilly's second capability centre in India, following LCCI Bengaluru ...

Eli Lilly and Company (Lilly), the American pharmaceutical company ... This will be the pharmaceutical giant’s second capability centre in India, following the launch of LCCI Bengaluru in 2016. The ...

Our Bengaluru-based LCCI has been highly successful, and Hyderabad provides the ideal combination of infrastructure, talent, and a thriving ecosystem to support our expansion,” a spokesperson for Eli ...